Eloxx Pharmaceuticals GAAP EPS of -$0.49 beats by $0.09
- Eloxx Pharmaceuticals press release (ELOX): Q3 GAAP EPS of -$0.49 beats by $0.09.
- As of September 30, 2026, the Company had cash and cash equivalents of $56.3 million, compared to $62.0 million as of June 30, 2026. The Company believes its cash and cash equivalents will be sufficient to fund its operations into 2028.
Recommended For You
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
Black Friday: Create a Free Seeking Alpha Account
See what's moving the market with unlimited news access, and get 20% off your first year of any Seeking Alpha service.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.